Polaroid Therapeutics

What Polaroid Therapeutics does

Polaroid Therapeutics AG is a Swiss biotech startup founded in 2022 and incubated by Polaroid, the brand historically known for instant photography. The company develops antimicrobial polymer technology for wound care and related medical applications, addressing the global antimicrobial resistance (AMR) crisis through a non-leaching structural antimicrobial approach rather than conventional chemical-release mechanisms. Its proprietary APT (Antimicrobial Polymer Technology) platform is based on quaternized polyethyleneimine (QPEI) polymer chemistry, which embeds antimicrobial functionality directly into dressing fibers and medical device materials to prevent bacterial colonization without contributing to AMR.

The company's first commercial product is POLTX_Fiber, a CE-marked Class IIb antimicrobial gelling fiber wound dressing made of sodium carboxymethylcellulose (CMC) fibers. The product received CE Mark certification from TÜV SÜd on February 23, 2026, and is positioned for management of moderate to heavily exuding acute and chronic wounds including leg ulcers, pressure ulcers, diabetic ulcers, surgical wounds, and cavity wounds. The dressing forms a gel upon contact with wound exudate, maintains a moist wound environment, supports autolytic debridement, and provides sustained antimicrobial activity over seven days with bacterial load reduction within three hours of application. Manufacturing is conducted under ISO 13485 quality standards. The company is preparing for commercial launch in selected European markets, with additional APT-powered medical devices, coatings, and therapeutic applications in the pipeline.

Polaroid Therapeutics operates a B2B medical device distribution model, selling POLTX_Fiber through distribution partners, clinicians, and wound care centers targeting healthcare institutions and wound care professionals — not directly to consumers. The company maintains operational entities in Switzerland (Schlieren, Zurich), the Netherlands (Amsterdam), and the United States. Revenue is not publicly disclosed and the company is in a pre-commercial stage with CE Mark just secured. Strategic partnerships include SFM Limited for CMC fiber manufacturing, the University of Hull for the £48M Wound Innovation Centre (co-funded with Reckitt and UK Research Partnership Investment Fund), and Ingenix.Ai for AI-augmented clinical workflows. The leadership team includes CEO and Co-Founder Ran Frenkel (25+ years pharma executive experience) and COO and Co-Founder Anne Graham.

Name

Polaroid Therapeutics

Legal name

Polaroid Therapeutics AG

Website

https://polaroidtherapeutics.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Polaroid Therapeutics is a Swiss biotech startup developing antimicrobial polymer technology for wound care. Its proprietary APT platform powers POLTX_Fiber, a CE-marked antimicrobial gelling fiber dressing sold to European healthcare institutions managing chronic and acute wounds.

Ownership category

akta.pro rank

Product category

Advanced Antimicrobial Wound Care Dressings

NAICS

Nonwoven Fabric Mills (31323), Textile and Fabric Finishing and Fabric Coating Mills (3133)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Antimicrobial Wound Care (Silver/Iodine/PHMB Dressings, Wound Irrigation) (HLAHALAC)

akta.pro secondary industries

Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film) (HLAHALAA), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Wound Care & Ulcer Management (HLAKACAN)

Keywords

• Antimicrobial wound dressings
• Polymer technology platform
• Advanced wound care
• Medical device coatings
• Chronic wound therapy

Headquarters

HQ city

Schlieren

HQ country

Switzerland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Product Sales (POLTX_Fiber): PTx generates revenue through the sale of its CE-marked POLTX_Fiber advanced wound care dressing, a Class IIb antimicrobial gelling fiber medical device. The company is preparing to launch in selected European markets through distribution partners, clinicians, and wound care centers, with additional APT-powered medical devices in development to expand the product portfolio.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Polaroid Therapeutics develops and manufactures advanced antimicrobial wound care dressings built on its proprietary APT (Antimicrobial Polymer Technology) platform based on quaternized polyethyleneimine (QPEI) polymer chemistry. Its first commercial product, POLTX_Fiber, is a CE-marked Class IIb antimicrobial gelling fiber wound dressing that prevents bacterial colonization within the dressing through a non-leaching structural mechanism, providing sustained antimicrobial activity for up to 7 days while maintaining a moist wound environment.

Product overview

Polaroid Therapeutics operates a platform-plus-product model built around its proprietary APT™ (Antimicrobial Polymer Technology) platform. The APT™ platform, based on quaternized polyethyleneimine (QPEI) polymer chemistry, provides controlled antimicrobial performance through structural design rather than chemical release. The first commercial application of this platform is POLTX_Fiber™, a CE Mark-certified Class IIb antimicrobial gelling fiber wound dressing that prevents bacterial colonization without contributing to antimicrobial resistance. The platform is designed to be adapted across wound management, medical device coatings (such as catheters and implants), and therapeutic applications including combination drugs and advanced delivery systems.

Differentiator

Problem solved

Functional benefit

Brands

• APT™ (Antimicrobial Polymer Technology): Proprietary platform technology that enables controlled antimicrobial performance through structural design rather than chemical release. Based on quaternized polyethyleneimine (QPEI) polymer chemistry adapted across multiple formats and clinical contexts.
• POLTX_Fiber™

Products and services

• POLTX_Fiber CE-marked Class IIb antimicrobial gelling fiber wound dressing incorporating APT technology. Soft, conformable non-woven dressing made of sodium carboxymethylcellulose (CMC) fibers and strengthening cellulose fibers. Prevents bacterial colonization within the dressing without contributing to antimicrobial resistance; forms a gel upon contact with wound exudate to maintain a moist wound environment. Indicated for management of moderate to heavily exuding acute and chronic wounds including leg ulcers, pressure ulcers, diabetic ulcers, surgical wounds, traumatic wounds, and cavity wounds.

Quantifiable outcome

• Bacterial load reduction within 3 hours of application
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered flagship, minor and core.

• ReckittflagshipStrategic or Co-development Partner · 15 May 2026Reckitt is an industry partner in the £48M Wound Innovation Institute at the University of Hull, co-funding the facility alongside PTx and the UK Research Partnership Investment Fund. The institute focuses on addressing the chronic wound crisis affecting approximately 2.2 million people in the UK.
• TÜV SüdminorOthers · 25 February 2026TÜV Süd is the notified body that granted CE Mark certification to POLTX_Fiber as a Class IIb medical device under MDR 2017/745 on February 23, 2026, enabling commercial launch in Europe.
• Ingenix.AicoreTechnology or Integration · 24 June 2025PTx partnered with Ingenix.Ai, a multimodal and multiscale generative AI company, to embed AI co-pilot technology into PTx's clinical workflows for wound management. The collaboration uses digital twins of the human body to simulate clinical trials, analyze multiscale biological data, and accelerate the development of APT-powered wound care therapies.
• University of HullcoreStrategic or Co-development Partner · 27 May 2025Polaroid Therapeutics partnered with the University of Hull to launch the world's first £48M international Wound Innovation Centre (WIC) in East Yorkshire. PTx joined the UK Research Partnership Investment Fund and industry partners (Reckitt) in pledging funding. The center will bring together academics, clinical researchers, and industry to address chronic wounds and antimicrobial resistance, with PTx's APT technology contributing to translational wound research.
• SFM LimitedcoreStrategic or Co-development Partner · 1 August 2024PTx partnered with SFM Limited, a UK manufacturer of specialist fabrics for advanced wound care dressings, to develop a novel carboxymethyl cellulose (CMC) dressing incorporating PTx's APT technology. The partnership involves a series of trials to evaluate feasibility of integrating APT into SFM's CMC fiber technology, with the goal of creating an innovative wound dressing for cavity wounds that prevents infection and aids healing.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Organogenesis: Regenerative medicine company with Apligraf and Dermagraft skin substitutes for chronic wounds. Comparable in therapeutic ambition (regenerative/advanced wound care) and serves overlapping diabetic foot ulcer and venous leg ulcer patient populations.
• MiMedx: Regenerative medicine company focused on advanced wound care and surgical recovery using placental tissue allografts. Comparable in scale and stage to PTx, addressing similar chronic and complex wound indications.

Direct peers

• Smith & Nephew: Global medical device leader with a substantial advanced wound care portfolio including antimicrobial silver dressings (ACTICOAT) and gelling fiber dressings (AQUACEL). Direct head-to-head competitor to POLTX_Fiber in European hospital channels.
• Urgo Medical: Specialist wound care company with UrgoCell Ag and a strong European presence in advanced antimicrobial dressings. Closely comparable mid-sized peer competing in similar clinical indications and channels.
• ConvaTec: Major advanced wound care player with AQUACEL Ag (silver-impregnated gelling fiber dressing), the closest direct analogue to POLTX_Fiber's gelling fiber format. Competes in the same hospital and chronic wound segments.
• Mölnlycke Health Care: Leading wound care specialist with Mepilex Ag (antimicrobial foam dressing) and Mepitel product lines. Competes directly with PTx in the antimicrobial and gelling fiber dressing categories across Europe.

Broad incumbents

• B. Braun: Global medical device and pharmaceutical company with Askina antimicrobial wound care line. Competes in hospital channels across Europe with a broad portfolio that overlaps with POLTX_Fiber.
• 3M Health Care (KCI): Diversified medical and wound care giant (post-Acelity acquisition) with antimicrobial dressings, NPWT, and skin integrity products. Competes broadly in advanced wound management and has the scale and capital to out-execute smaller entrants.
• Coloplast: Broad medical device company with a sizeable wound and skin care business (Biatain Ag). Strong European distribution and home-care channels that compete for the same clinician and patient demand PTx targets.
• Integra LifeSciences: Specialty medical device company with a wound care portfolio including antimicrobial dressings and regenerative skin products. Competes in chronic wound and surgical wound segments targeted by POLTX_Fiber.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/polaroid-therapeutics

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Polaroid Therapeutics